In addition to the upcoming SPaL Phase 3 trial, TB Alliance plans to explore delivering a sorfequiline-based regimen as a long-acting injectable (LAI), a formulation that could potentially help reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback